THT 2023: Heart Failure Cardiogenic Shock – Unique Phenotype and tMCS Considerations
By
Getinge
FEATURING
Rachna Kataria
By
Getinge
FEATURING
Rachna Kataria
Welcome to the second presentation within the session, "THT 2023: MCS device selection in HF patients - Where does counterpulsation fit?", from the 2023 Technology and Heart Failure Therapeutics Conference.
The full-length session focuses on the unique physiological effects of counterpulsation in advanced heart failure patients. Moreover, the session provides guidance on MCS selection based on underlying etiology, clinical phenotyping, and predictors for positive hemodynamic and clinical response. Finally, you will be presented with novel applications for counterpulsation in HF.
To watch the full-length session, click here.
Comments 0
Login to view comments.
Click here to Login
